secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001628280-24-045984
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q3 revenue $51.6M (+52% YoY); net loss narrows to $29.5M
-----------------------------------------------------------------

- Total revenue $51.6M (+52% YoY); U.S. net product revenue $31.1M (+53% YoY).
- Net loss $29.5M (EPS -$0.15) vs. $41.3M loss (-$0.37) in Q3 2023.
- Cash & equivalents $144.7M at Sep 30, up from $82.2M at Dec 31, 2023.
- Retail prescription equivalents +12% QoQ; Oct 2024 TRx +17% vs. first 4 weeks of Q3.
- European partner DSE royalty revenue $8.9M (+19% sequentially); Otsuka on track for Japan NDA filing by end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024045984/0001628280-24-045984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024045984/espr-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer